ALK花生过敏治疗显示 早期临床试验很有前途 计划进一步测试 ALK's peanut allergy treatment shows promise in early clinical trial, with plans for further testing.

ALK对花生过敏治疗的临床试验显示出积极的结果,在对30名病人的试验中,亚语言免疫疗法药片证明是安全且可容忍的。 ALK's clinical trial for a peanut allergy treatment showed positive results, with the sublingual immunotherapy tablet proving safe and tolerable in a trial of 30 patients. 轻微的副作用是常见的,但短暂的。 Mild side effects were common but transient. 下一阶段涉及约125名病人,将测试两种剂量疗程,定于2026年结束。 The next phase, involving about 125 patients, will test two dosing regimens and is set to conclude in 2026. 成功可能导致治疗花生过敏的进一步发展和可能的核准,这种过敏影响到美国多达150万儿童和青少年。 Success could lead to further development and potential approval for treating peanut allergies, which affect up to 1.5 million children and adolescents in the US.